147 related articles for article (PubMed ID: 22816494)
1. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma.
Sahora AI; Rusk AW; Henkin J; McKeegan EM; Shi Y; Khanna C
J Vet Intern Med; 2012; 26(5):1169-76. PubMed ID: 22816494
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
[TBL] [Abstract][Full Text] [Related]
3. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma.
Burton JH; Mitchell L; Thamm DH; Dow SW; Biller BJ
J Vet Intern Med; 2011; 25(4):920-6. PubMed ID: 21736624
[TBL] [Abstract][Full Text] [Related]
4. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Rusk A; Cozzi E; Stebbins M; Vail D; Graham J; Valli V; Henkin J; Sharpee R; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7456-64. PubMed ID: 17189419
[TBL] [Abstract][Full Text] [Related]
5. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.
Gordon MS; Mendelson D; Carr R; Knight RA; Humerickhouse RA; Iannone M; Stopeck AT
Cancer; 2008 Dec; 113(12):3420-9. PubMed ID: 18932258
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
Silver M; Rusk A; Phillips B; Beck E; Jankowski M; Philibert J; Hahn K; Hershey E; McKeegan E; Bauch J; Krivoshik A; Khanna C
J Vet Intern Med; 2012; 26(2):349-54. PubMed ID: 22369215
[TBL] [Abstract][Full Text] [Related]
9. Chronic effects of an anti-angiogenic thrombospondin-1 mimetic peptide, ABT-898, on female mouse reproductive outcomes.
Edwards AK; Olariu I; Nakamura DS; Ahn SH; Tayade C
Reprod Biol Endocrinol; 2016 Sep; 14(1):56. PubMed ID: 27604347
[TBL] [Abstract][Full Text] [Related]
10. Chronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in mice.
Audet GN; Fulks D; Stricker JC; Olfert IM
PLoS One; 2013; 8(2):e55953. PubMed ID: 23405239
[TBL] [Abstract][Full Text] [Related]
11. Soft-tissue sarcomas in dogs: a review.
Ehrhart N
J Am Anim Hosp Assoc; 2005; 41(4):241-6. PubMed ID: 15995161
[TBL] [Abstract][Full Text] [Related]
12. Serum vascular endothelial growth factor in dogs with soft tissue sarcomas.
de Queiroz GF; Dagli ML; Meira SA; Matera JM
Vet Comp Oncol; 2013 Sep; 11(3):230-5. PubMed ID: 22372675
[TBL] [Abstract][Full Text] [Related]
13. Metronomic chemotherapy.
Mutsaers AJ
Top Companion Anim Med; 2009 Aug; 24(3):137-43. PubMed ID: 19732732
[TBL] [Abstract][Full Text] [Related]
14. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
15. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).
Ettinger SN; Scase TJ; Oberthaler KT; Craft DM; McKnight JA; Leibman NF; Charney SC; Bergman PJ
J Am Vet Med Assoc; 2006 Apr; 228(7):1053-62. PubMed ID: 16579784
[TBL] [Abstract][Full Text] [Related]
16. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas.
Elmslie RE; Glawe P; Dow SW
J Vet Intern Med; 2008; 22(6):1373-9. PubMed ID: 18976288
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of local toxic effects and outcomes for dogs undergoing marginal tumor excision with intralesional cisplatin-impregnated bead placement for treatment of soft tissue sarcomas: 62 cases (2009-2012).
Bergman NS; Urie BK; Pardo AD; Newman RG
J Am Vet Med Assoc; 2016 May; 248(10):1148-56. PubMed ID: 27135671
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs.
Perry JA; Culp WT; Dailey DD; Eickhoff JC; Kamstock DA; Thamm DH
Vet Comp Oncol; 2014 Jun; 12(2):106-13. PubMed ID: 22617002
[TBL] [Abstract][Full Text] [Related]
20. Analysis of platinum content in biodegradable carboplatin-impregnated beads and retrospective assessment of tolerability for intralesional use of the beads in dogs following excision of subcutaneous sarcomas: 29 cases (2011-2014).
Hess TA; Drinkhouse ME; Prey JD; Miller JM; Fettig AA; Carberry CA; Brenn SH; Bailey DB
J Am Vet Med Assoc; 2018 Feb; 252(4):448-456. PubMed ID: 29393745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
